DANCR and breast cancer: Studies have confirmed that lidocaine and bupivacaine inhibit BC progression by activating the DANCR/miR-187-5p/MYB regulatory axis [30]; in addition, in terms of epigenetic modifications, Zhou et al. discovered that METTL3 enhances the stability of the DANCR mRNA through the m6A modification to promote osteosarcoma (OS) progression [31].